Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Portosystemic Encephalopathy Clear all
Completed Not applicable Interventional Results available

The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.

NCT04675775
View directory record Official record
Conditions
Cirrhosis, Ascites, Liver Diseases, Frailty, Sarcopenia, Hepatic Encephalopathy
Interventions
Medically-tailored meals (MTM), Protein supplements, Nutrition education handout
Other · Dietary Supplement · Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 20, 2026, 8:44 PM EDT
Recruiting Not applicable Interventional

Affect of Melatonin on Sleep and Cognition in Cirrhosis

NCT07046429
View directory record Official record
Conditions
Hepatic Encephalopathy, Covert Hepatic Encephalopathy, Cirrhosis, Sleep Disturbances and Insomnia
Interventions
Melatonin tablet 3 mg once daily, Thiamine
Dietary Supplement
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

NCT03515044
View directory record Official record
Conditions
Overt Hepatic Encephalopathy
Interventions
40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
34
States / cities
Corona del Mar, California • Los Angeles, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 4 Interventional Results available

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

NCT01842581
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
43
States / cities
Phoenix, Arizona • Coronado, California • Fresno, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Not applicable Interventional Results available

Rifaximin in Minimal Hepatic Encephalopathy

NCT00533910
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, placebo
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 8:44 PM EDT
Not yet recruiting No phase listed Observational

Revealing Engagement Patterns Among Hepatic Encephalopathy Patients

NCT06201988
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Not listed
Lead sponsor
Power Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Not applicable Interventional

Telehealth Intervention in Cirrhotics

NCT03969186
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Diseases
Interventions
Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Results available

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

NCT03712280
View directory record Official record
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 20, 2026, 8:44 PM EDT
Not yet recruiting Phase 2 Interventional

Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)

NCT07528690
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Microbiota transplant therapy (MTT) capsules, Placebo capsule
Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
West Haven, Connecticut • Dallas, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 8:44 PM EDT
Withdrawn Not applicable Interventional

HepQuant to Predict Hepatic Encephalopathy After TIPS

NCT04664621
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
HepQuant
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 1Phase 2 Interventional

Study of Rifaximin in Minimal Hepatic Encephalopathy

NCT01069133
View directory record Official record
Conditions
Minimal Hepatic Encephalopathy
Interventions
rifaximin
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 11, 2012 · Synced Oct 20, 2026, 8:44 PM EDT
Completed No phase listed Observational

TIPS Plus Transvenous Obliteration for Gastric Varices

NCT04044248
View directory record Official record
Conditions
Cirrhosis, Liver, Hypertension, Portal, Esophageal and Gastric Varices, Bleeding Gastric, Encephalopathy
Interventions
TIPS-obliteration
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Not applicable Interventional

Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration

NCT05526404
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Dieta mobile application
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 18, 2023 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Trial to Improve Quality of Life in People With Cirrhosis

NCT05061992
View directory record Official record
Conditions
Cirrhosis
Interventions
Lactulose
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 20, 2026, 8:44 PM EDT
Withdrawn Phase 3 Interventional

A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure

NCT02086825
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 20, 2026, 8:44 PM EDT
Terminated Phase 3 Interventional Results available

RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial

NCT00364689
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin, Lactulose, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 8:44 PM EDT
Not listed Not applicable Interventional

Timing of Acute Palliative Care Consultation in Critically Ill Patients

NCT02858778
View directory record Official record
Conditions
Multiple Organ Failure, End Stage Cardiac Failure, End Stage Chronic Obstructive Airways Disease, Chronic Kidney Disease Stage 5, Hepatic Encephalopathy, Sepsis, Dementia, Multiple Sclerosis, Parkinson's Disease, In-Hospital Cardiac Arrest, Solid Organ Cancer
Interventions
Early order of palliative care consultation
Other
Lead sponsor
Wayne State University
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
2
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 20, 2026, 8:44 PM EDT
Withdrawn Not applicable Interventional

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

NCT01923376
View directory record Official record
Conditions
Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions
Lactulose, Polyethylene Glycol 3350
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 20, 2026, 8:44 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

NCT05071716
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin SSD, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
139
States / cities
Dothan, Alabama • Chandler, Arizona • Peoria, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Not applicable Interventional

A Study of Controlled Lactulose Withdrawal

NCT00914056
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
lactulose
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 20, 2026, 8:44 PM EDT
Completed Phase 2 Interventional Results available

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

NCT01966419
View directory record Official record
Conditions
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions
ornithine phenylacetate, placebo intravenous infusion
Drug
Lead sponsor
Ocera Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 20, 2026, 8:44 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Factors Associated With End Stage Liver Disease

NCT01846819
View directory record Official record
Conditions
Cirrhosis, Hepatic Encephalopathy, Fatigue, Depression
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 20, 2026, 8:44 PM EDT
Recruiting Not applicable Interventional

Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

NCT06425380
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis
Interventions
Resistant Potato Starch
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 20, 2026, 8:44 PM EDT
Not listed No phase listed Observational

Flicker App for Minimal Hepatic Encephalopathy

NCT04415294
View directory record Official record
Conditions
Hepatic Encephalopathy
Interventions
Critical flicker frequency
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 20, 2026, 8:44 PM EDT